Other Diseases
Mirum completes enrollment of Phase IIb trial for biliary atresia
Mirum has completed enrollment for its Phase IIb EMBARK study evaluating Livmarli (maralixibat) in infants with biliary atresia who have…
Omega-3 Fatty Acids May Reduce Risk of Chronic Kidney Disease
Chronic kidney disease (CKD) is a condition characterised by a gradual loss of kidney function over time, leading to the…
Pipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops
In this week’s Pipeline Moves, we start off with the termination of an investigator-led Phase II cancer study of Roche’s…
Failure for Servier and Neurochlore’s autism drug, but potential remains in market
On 7 September, Servier and Neurochlore announced that following a lack of efficacy of bumetanide for autism spectrum disorder (ASD)…
Revised Covid-19 vaccine prices likely by the fall in the US but premium pricing possibility debatable
Companies with authorised Covid-19 vaccines in the US are likely to launch renegotiated prices as soon as the fall, experts…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Astellas awarded funding for opioid use disorder trials of ASP8062
Japan-based Astellas Pharma has received a grant from the US National Institutes of Health (NIH) unit to support two Phase…
BeiGene’s Phase III Trial of Zanubrutinib Misses Late-Stage Goals in Waldenström’s Macroglobulinemia
Beigene announced that its Phase III Trial of zanubrutinib compared to Johnson & Johnson/AbbVie’s ibrutinib did not achieve statistical significance…
Previously approved IDH2 inhibitor seeks label expansion in acute myeloid leukaemia
The first interim results from Celgene’s open-label, randomised Phase II (NCT02677922) study were announced at the 2019 annual American Society…
Biogen will pursue aducanumab approval despite scepticism about the data presented
At the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in San Diego on 5 December, Biogen presented additional details…
Ubrogepant is shown to effectively treat migraine symptoms
Irish pharmaceutical company Allergan’s ubrogepant is currently in pre-registration for the treatment of acute migraines. It's an oral pill belonging…